CA2601380A1 - Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases - Google Patents

Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases Download PDF

Info

Publication number
CA2601380A1
CA2601380A1 CA002601380A CA2601380A CA2601380A1 CA 2601380 A1 CA2601380 A1 CA 2601380A1 CA 002601380 A CA002601380 A CA 002601380A CA 2601380 A CA2601380 A CA 2601380A CA 2601380 A1 CA2601380 A1 CA 2601380A1
Authority
CA
Canada
Prior art keywords
compound
optionally substituted
alkyl
mmol
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002601380A
Other languages
English (en)
French (fr)
Inventor
Stephen Schlachter
John Gaudino
Laurence Burgess
Kevin Hunt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2601380A1 publication Critical patent/CA2601380A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002601380A 2005-01-20 2006-01-19 Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases Abandoned CA2601380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64555205P 2005-01-20 2005-01-20
US60/645,552 2005-01-20
PCT/US2006/001747 WO2006078724A2 (en) 2005-01-20 2006-01-19 Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases

Publications (1)

Publication Number Publication Date
CA2601380A1 true CA2601380A1 (en) 2006-07-27

Family

ID=36692822

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002601380A Abandoned CA2601380A1 (en) 2005-01-20 2006-01-19 Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases

Country Status (8)

Country Link
US (1) US7553842B2 (cg-RX-API-DMAC10.html)
EP (1) EP1838316A4 (cg-RX-API-DMAC10.html)
JP (1) JP2008528491A (cg-RX-API-DMAC10.html)
AU (1) AU2006206525A1 (cg-RX-API-DMAC10.html)
CA (1) CA2601380A1 (cg-RX-API-DMAC10.html)
MX (1) MX2007008662A (cg-RX-API-DMAC10.html)
TW (1) TW200637552A (cg-RX-API-DMAC10.html)
WO (1) WO2006078724A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0904540D0 (en) * 2009-03-17 2009-04-29 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) * 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) * 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
IT1401451B1 (it) * 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
EP3433259B1 (en) * 2016-03-24 2021-06-30 The Administrators of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
CA3043575A1 (en) * 2016-11-10 2018-05-17 Novartis Ag Bmp potentiators
CN108148032B (zh) * 2018-03-01 2019-12-13 北京海步医药科技股份有限公司 一种3,4-二氢-2h-1-苯并吡喃-2-羧酸类化合物的制备方法及其应用
CN119751235A (zh) * 2019-01-23 2025-04-04 约翰霍普金斯大学 非免疫抑制性fk506类似物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2245891A (en) 1990-07-09 1992-01-15 Fujisawa Pharmaceutical Co Tricyclo compounds
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5457111A (en) * 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5563172A (en) * 1991-09-05 1996-10-08 Abbott Laboratories Macrocyclic amide and urea immunomodulators
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
WO1994021634A1 (en) * 1993-03-17 1994-09-29 Abbott Laboratories Substituted alicyclic-aliphatic amine-containing macrocyclic immunomodulators
US5457194A (en) * 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
WO1994021254A1 (en) * 1993-03-17 1994-09-29 Abbott Laboratories Substituted alicyclic amine-containing macrocyclic immunomodulators
WO1994021642A1 (en) * 1993-03-17 1994-09-29 Abbott Laboratories Macrocyclic amide and urea immunomodulators
US6093615A (en) * 1994-08-15 2000-07-25 Micron Technology, Inc. Method of fabricating a contact structure having a composite barrier layer between a platinum layer and a polysilicon plug
DE19859467C2 (de) * 1998-12-22 2002-11-28 Steag Micro Tech Gmbh Substrathalter
US6569867B2 (en) * 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives

Also Published As

Publication number Publication date
AU2006206525A2 (en) 2006-07-27
TW200637552A (en) 2006-11-01
AU2006206525A1 (en) 2006-07-27
EP1838316A4 (en) 2012-01-25
WO2006078724A3 (en) 2008-01-24
US20060160838A1 (en) 2006-07-20
EP1838316A2 (en) 2007-10-03
US7553842B2 (en) 2009-06-30
JP2008528491A (ja) 2008-07-31
WO2006078724A2 (en) 2006-07-27
MX2007008662A (es) 2007-09-06

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
US7868024B2 (en) Derivatives of N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamides, preparation thereof and therapeutic use thereof
CA3157177C (en) Compounds containing the pyran moiety
CN112566916B (zh) 作为pad4抑制剂的经取代的噻吩并吡咯
RU2733402C2 (ru) Бициклические арильные монобактамовые соединения и способы их применения для лечения бактериальных инфекций
AU2022271425A1 (en) Processes of making and crystalline forms of a MDM2 inhibitor
US11634412B2 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
AU2021246147B2 (en) RIP1K inhibitors
US8921363B2 (en) Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
EP3426244B1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
CN112300153B (zh) 一种杂环化合物、药物组合物和用途
KR20220042206A (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
CA2956465A1 (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
JP2014526560A (ja) β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
CA3170664A1 (en) P2x3 modulators
US8822485B2 (en) Amino heteroaryl compounds as beta-secretase modulators and methods of use
US7226906B2 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US7553842B2 (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
KR20010042307A (ko) 피롤로[1,2-a]피라진 sPLA2 억제제
WO2024125624A1 (en) Sarm1 modulators, preparations, and uses thereof
US20060270675A1 (en) Inhibitors of cholesterol ester transfer protein
CN117447460A (zh) 作为ripk1抑制剂的杂环化合物
WO1999067239A1 (en) Pyrazolopyridine compounds and medicinal uses thereof
HK40096020B (zh) Mtorc1调节剂及其用途
HK40096020A (en) Mtorc1 modulators and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued